This is a Phase 2, single-arm study to evaluate the safety and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (PDAC).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Progression-Free Survival (PFS)
Timeframe: From date of enrollment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months